Legend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024. In the quarter to June 2026, revenue grew 51.9%, EPS grew 126.1%, free cash flow fell 26.8% and total debt fell 49.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow LEGN
Legend Biotech Corporation Sponsored ADR (LEGN) EV/Sales
As of 16 October 2026, Legend Biotech Corporation Sponsored ADR (LEGN) trades at a EV/Sales of 2.2×. Over the past ten years it has ranged from 0.0× (March 2019) to 101× (June 2023); the current reading is higher than 2% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.4× | (63.91%) |
| FY2024 | 9.6× | (77.04%) |
| FY2023 | 41.6× | (43.69%) |
| FY2022 | 73.9× | (12.29%) |
| FY2021 | 84.3× | 144.19% |
| FY2020 | 34.5× | (37.27%) |
| FY2019 | 55.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.7× | 44.59% |
| Mar 2026 | 2.6× | (24.88%) |
| Dec 2025 | 3.4× | (41.31%) |
| Sep 2025 | 5.9× | (20.35%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TLX Telix Pharmaceuticals Limited compare | n/m |
| EWTX Edgewise Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR | 2.2× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 4.3× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 7.8× |
| TNGX Tango Therapeutics, Inc. compare | 36.7× |
| ABCL AbCellera Biologics Inc. compare | 46.0× |
| RLAY Relay Therapeutics, Inc. compare | 217× |
| DNTH Dianthus Therapeutics, Inc. compare | 1,656× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)